Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Bitcoin ETF's Impact on Market Takes Time, Bitcoin Price Could Face New Highs

Bitcoin ETF's Impact on Market Takes Time, Bitcoin Price Could Face New Highs

2024/04/05 18:34

While it is widely believed that Bitcoin ETFs will quickly change the Bitcoin market, top traders believe that it will take years for the impact of ETFs to be fully realized.ETFs offer a new way for the average investor to invest in Bitcoin without buying cryptocurrency directly. For now, any money flowing into Bitcoin as a result of ETFs is just extra help. Traders believe that it will become apparent in the future that ETFs will bring more money to Bitcoin.

This argument makes sense in the slow-moving world of traditional finance, but it's not a guarantee. If the rules around them are clear and the crypto world continues to improve, ETFs could help stabilize the price of Bitcoin. Currently, the price of Bitcoin is around $66,000. If ETF inflows remain, the price of Bitcoin could be higher for the foreseeable future and long term. The next significant price target could be $69,000. The attraction of traditional funds is a positive trend for digital gold, but ETFs are still evolving and their true impact on the market will take time to see.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11

SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.

The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).

智通财经2026/09/22 07:11